Company profile
BB-NCIPD EAD is a commercial company, 100% state-owned, with over 130 years of history.
BB-NCIPD EAD became a separate entity at the end of 2000 based on the production department of the National Center of Infectious and Parasitic Diseases that had a long history in the manufacture of biopreparations. (see Historical notes) BB-NCIPD EAD belongs to the Ministry of Health of Bulgaria.
BB-NCIPD EAD has inherited a skilled workforce of highly qualified physicians, pharmacists, biologists, chemists, economists and supporting personnel. Prominent specialists with higher education and high qualified staff with secondary special education work in production, control and quality assurance, which represent over 80% of the company’s staff.
The management is introducing European standards in personnel training, staff motivation and incentives, improving constantly the educational and qualification level of the employees.
The production nomenclature covers more than 600 medicines, divided in two main groups: human medicines and in-vitro diagnostic medicine products. As result of the research and development activity of the company specialists, there have been implemented new technologies meeting the highest requirements of the international standards.
The prophylactic, medicinal diagnostic products and nutrient media for infectious diseases control comply with the highest current requirements.
The company largely meets the needs of the immunization program in Bulgaria through highly effective vaccines.
The vaccines and other products comply with the WHO and European Pharmacopoeia requirements. The production of BB-NCIPD EAD satisfies a large part of the country's necessity of high-quality, effective and safe medicines for treatment, prophylactics and diagnostics of infectious diseases.
The production of immunostimulators Respivax, Urostim, Calgevax and Dentavax has been developing for the past several decades, and all have proved highest efficiency and are well accepted in Bulgaria and abroad.
The bioproducts of BB-NCIPD EAD such as BCG vaccine, PPD Tuberculin, vaccines against diphtheria, tetanus, and pertussis, immunostimulators and allergens etc. are exported in over 90 countries in the world and this export forms more than 40% of its revenues.
The production of drugs for human medicine is fulfilled by high-qualified specialists in premises, installation, and equipment, which meet the Good Manufacturing Practice requirements. BB-NCIPD EAD holds production license No. I-65/12.02.2003, issued by the Bulgarian Drug Agency, which approves it as a manufacturer, who meets the requirements of Human Medicines and Pharmacies Act.
BB-NCIPD EAD maintains a quality management system, an environmental system and information security system covering the requirements of the international standards ISO 9001:2015, ISO 14001:2015 and ISO 27001:2022.